Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
Sarah Gordon, William P. McGuire, Danielle Shafer, et al.
American Journal of Clinical Oncology (2019) Vol. 42, Iss. 8, pp. 649-654
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke, Nina Reßing, Finn K. Hansen, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 634-634
Open Access | Times Cited: 137
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 7
Advances in epigenetic therapeutics with focus on solid tumors
Ning Jin, Tiffany L. George, Gregory A. Otterson, et al.
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 84
Epigenetic remodelling in human hepatocellular carcinoma
Maria Rita Braghini, Oriana Lo Re, Ilaria Romito, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 55
Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
Katarzyna Roszkowska, Aleksandra Piecuch, Maria Sady, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13287-13287
Open Access | Times Cited: 32
Current trends and future prospects of drug repositioning in gastrointestinal oncology
Nayeralsadat Fatemi, Mina Karimpour, Hoda Bahrami, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 6
Annonaceous Acetogenins Synergistically Inhibit Hepatocellular Carcinoma with Sorafenib
Rongsheng Li, Lingyun Li, Xiaofeng Zhu, et al.
Journal of Natural Products (2024) Vol. 87, Iss. 1, pp. 14-27
Closed Access | Times Cited: 6
Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 3, pp. 223-223
Open Access | Times Cited: 26
Epigenetic Regulation of Epithelial to Mesenchymal Transition in the Cancer Metastatic Cascade: Implications for Cancer Therapy
Qiu-Luo Liu, Maochao Luo, Canhua Huang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 26
c-FLIP/Ku70 complex; A potential molecular target for apoptosis induction in hepatocellular carcinoma
Yasamin Haghir-Sharif-Zamini, Arezoo Khosravi, Moustapha Hassan, et al.
Archives of Biochemistry and Biophysics (2025), pp. 110306-110306
Closed Access
The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells
Jane L. Roberts, Andrew Poklepovic, Laurence Booth, et al.
Cellular Signalling (2020) Vol. 70, pp. 109573-109573
Closed Access | Times Cited: 27
HDACIs and TKIs combinations and their liposomal delivery for cancer treatment
Cindy Schelker, Patrycja Nowak‐Sliwinska, Gerrit Borchard
Journal of Controlled Release (2023) Vol. 358, pp. 59-77
Open Access | Times Cited: 9
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer
Laurence Booth, Andrew Poklepovic, Paul Dent
Biochemical Pharmacology (2020) Vol. 178, pp. 114067-114067
Open Access | Times Cited: 22
Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor‐Initiating Stem‐Like Cells
Chia‐Lin Chen, Juan Carlos Hernandez, Dinesh Babu Uthaya Kumar, et al.
Advanced Science (2023) Vol. 10, Iss. 14
Open Access | Times Cited: 7
Epigenetic therapeutic strategies in pancreatic cancer
Arturo Orlacchio, Stephen Muzyka, Tamas A. Gonda
International review of cell and molecular biology (2024), pp. 1-40
Closed Access | Times Cited: 2
Dose–response prediction for in-vitro drug combination datasets: a probabilistic approach
Leiv Rønneberg, Paul Kirk, Manuela Zucknick
BMC Bioinformatics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells
Laurence Booth, Jane L. Roberts, Andrew Poklepovic, et al.
Anti-Cancer Drugs (2023)
Closed Access | Times Cited: 6
Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43
Paul Dent, Laurence Booth, Jane L. Roberts, et al.
Aging (2021) Vol. 13, Iss. 13, pp. 17097-17117
Open Access | Times Cited: 13
Multifaceted Influence of Histone Deacetylases on DNA Damage Repair: Implications for Hepatocellular Carcinoma
Gan Du, Ruizhe Yang, Jianguo Qiu, et al.
Journal of Clinical and Translational Hepatology (2022) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 5
Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer
Sofia I. Bär, Alexandra Dittmer, Bianca Nitzsche, et al.
International Journal of Oncology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 4
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021
Zachary J. Brown, D. Brock Hewitt, Timothy M. Pawlik
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 7, pp. 693-706
Closed Access | Times Cited: 3
<p>Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib</p>
Xuan Qiu, Manjiang Li, Liqun Wu, et al.
Cancer Management and Research (2020) Vol. Volume 12, pp. 7983-7992
Open Access | Times Cited: 3
An Updated Comprehensive Pharmacovigilance Study of Drug‐Induced Thrombocytopenia Based on FDA Adverse Event Reporting System Data
Li Kun-yu, Shi Shuping, Chang Su, et al.
The Journal of Clinical Pharmacology (2023) Vol. 64, Iss. 4, pp. 478-489
Closed Access | Times Cited: 1
Novel Approaches to Treat Glioblastoma Multiforme
Mark G. Malkin, Laurence Booth, Jane L. Roberts, et al.
EMJ Oncology (2024), pp. 110-115
Open Access
ADENOSINE RECEPTOR 3 IN LIVER CANCER: EXPRESSION VARIABILITY, EPIGENETIC MODULATION, AND ENHANCED HDAC INHIBITOR EFFECTS
Louise Kaldjob-Heinrich, Sandro Nuciforo, Steffen Lemke, et al.
Gastro Hep Advances (2024) Vol. 4, Iss. 3, pp. 100590-100590
Open Access
Page 1 - Next Page

Scroll to top